Celator Pharmaceuticals Announces Positive Induction Response Results from Phase 3 Study of CPX-351 in Patients with High-Risk Acute Myeloid Leukemia

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.